Assessing long-term outcomes of LAA contrast flow after heart procedure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the long-term outcomes of left atrial appendage (LAA) contrast flow in patients who have undergone LAA closure using FDA-approved devices. It will involve a retrospective review of approximately 100 patient charts to investigate the incidence of peri-device leaks, device-related thrombosis, and the occurrence of strokes or transient ischemic attacks. The study seeks to understand the correlation between LAA contrast flow and the effectiveness of the closure devices over time, particularly in high-risk patients transitioning from anticoagulation to antiplatelet therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects must be at least 18 years of age.
* Subjects underwent LAA closure with Watchman/Watchman FLX or Amplatzer Amulet at our institution from January 2019 till June 2022

Exclusion Criteria:

* No definite exclusion criteria are defined for the study as all patients with Watchman-FLX or Amplatzer Amulet will be included in the study.

Where it's running

• Kansas City Heart Rhythm Institute
  Overland Park, Kansas, United States Recruiting

Study contacts

• Principal investigator: Dhanunjaya Lakkireddy, MD — Kansas City Heart Rhythm Institute
• Study coordinator: Donita Atkins
• Email: datkins@kchrf.com
• Phone: 816-651-1969

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals

  This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.

  Recruiting at 2 sites Hospital Universitari Vall d'Hebron Research Institute · Leuven and 6 other locations · NCT07924371

• Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities

  This study tests how comorbid conditions like sleep apnea and primary aldosteronism relate to left-atrial fibrosis and AF recurrence in patients undergoing ablation.

  Recruiting University Hospital Augsburg · Augsburg, Bavaria · NCT07857044

• Dual Energy ablation with SmartTouch SF catheter in persistent atrial fibrillation

  This study tests a pulsed field and radiofrequency ablation system to treat persistent atrial fibrillation in adults who have not responded well to prior medications.

  Recruiting at 4 sites Biosense Webster, Inc. · Beijing and 3 other locations · NCT07845682

• Identifying AF patients who may need more than standard ablation using Volta AF-Xplorer II

  This trial tests whether AI-identified dispersion areas during AF ablation can predict recurrence after a standard pulmonary vein isolation in patients with persistent AF.

  Recruiting Volta Medical · Avignon and 4 other locations · NCT07807423

• 4D intracardiac echocardiography to guide left atrial appendage occlusion procedures

  A new 4D ICE catheter is being tested alongside standard imaging to see if it can safely guide left atrial appendage occlusion procedures for adults with atrial fibrillation.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07806890

• AI-powered decision support to boost thrombolysis for ischemic stroke

  This trial tests whether an AI-assisted decision tool helps doctors give intravenous thrombolysis to eligible ischemic stroke patients within 24 hours at a primary hospital in China, compared with standard care.

  Recruiting Capital Medical University · Changsha, Hunan · NCT07785492

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.